Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000589
Abstract: The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole… read more here.
Keywords: qtc; advanced breast; breast cancer; plus letrozole ... See more keywords
Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p1-19-02
Abstract: Background: Palbociclib (PB), the first clinically available oral CDK4/6 inhibitor, in combination with endocrine therapy has become standard of care for HR+/HER2- advanced/metastatic breast cancer (MBC). The phase III PALOMA-2 trial demonstrated significant progression-free survival… read more here.
Keywords: palbociclib; plus letrozole; breast cancer; metastatic breast ... See more keywords
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial
Sign Up to like & getrecommendations! Published in 2021 at "BMC Cancer"
DOI: 10.1186/s12885-021-08612-y
Abstract: Background Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. Methods Postmenopausal women with ER-positive, HER2-negative breast… read more here.
Keywords: breast; positive her2; plus letrozole; neoadjuvant everolimus ... See more keywords
Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.865292
Abstract: Background Cyclin-dependent kinase 4/6 inhibitors are a standard treatment for patients with hormone receptor−positive (HR+)/human epidermal growth factor receptor 2−negative (HER2−) metastatic breast cancer (MBC). However, real-world data on effectiveness in patients with liver or… read more here.
Keywords: metastasis; palbociclib plus; plus letrozole; letrozole alone ... See more keywords